Shares of I-Mab (IMAB) touched a new 52-week high of $6.72 yesterday as the company gears up to present updated Givastomig monotherapy data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025.
Givastomig, the company's lead drug candidate, is a bispecific antibody targeting Claudin 18.2-positive tumor cells. It conditionally activates T cells through the 4-1BB signalling pathway in the tumour microenvironment, where CLDN18.2 is expressed. CLDN18.2 is a protein that is often expressed in various cancer types, including gastric and gastroesophageal adenocarcinomas. (Source: PubMed).
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.